JP2019516726A5 - - Google Patents

Download PDF

Info

Publication number
JP2019516726A5
JP2019516726A5 JP2018560644A JP2018560644A JP2019516726A5 JP 2019516726 A5 JP2019516726 A5 JP 2019516726A5 JP 2018560644 A JP2018560644 A JP 2018560644A JP 2018560644 A JP2018560644 A JP 2018560644A JP 2019516726 A5 JP2019516726 A5 JP 2019516726A5
Authority
JP
Japan
Prior art keywords
headache
general formula
pharmaceutical composition
migraine
alkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2018560644A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019516726A (ja
JP6986521B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/KR2017/005171 external-priority patent/WO2017200316A1/ko
Publication of JP2019516726A publication Critical patent/JP2019516726A/ja
Publication of JP2019516726A5 publication Critical patent/JP2019516726A5/ja
Application granted granted Critical
Publication of JP6986521B2 publication Critical patent/JP6986521B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2018560644A 2016-05-19 2017-05-18 頭痛の予防的治療のためのカルバメート化合物の使用 Active JP6986521B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
KR20160061374 2016-05-19
KR10-2016-0061374 2016-05-19
PCT/KR2017/005171 WO2017200316A1 (ko) 2016-05-19 2017-05-18 두통의 예방학적 치료를 위한 카바메이트 화합물의 용도

Publications (3)

Publication Number Publication Date
JP2019516726A JP2019516726A (ja) 2019-06-20
JP2019516726A5 true JP2019516726A5 (enExample) 2020-07-02
JP6986521B2 JP6986521B2 (ja) 2021-12-22

Family

ID=60325338

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2018560644A Active JP6986521B2 (ja) 2016-05-19 2017-05-18 頭痛の予防的治療のためのカルバメート化合物の使用

Country Status (8)

Country Link
US (2) US10456376B2 (enExample)
EP (1) EP3459541B1 (enExample)
JP (1) JP6986521B2 (enExample)
KR (1) KR102421006B1 (enExample)
CN (1) CN109310670B (enExample)
CA (1) CA3024278A1 (enExample)
ES (1) ES2893456T3 (enExample)
WO (1) WO2017200316A1 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2973111T3 (es) * 2017-11-14 2024-06-18 Sk Biopharmaceuticals Co Ltd Uso de un compuesto de carbamato para prevenir o tratar enfermedades asociadas con el aumento de la corriente tardía de sodio
CA3113052A1 (en) * 2018-09-21 2020-03-26 Sk Biopharmaceuticals Co., Ltd. Use of carbamate compound for prevention, alleviation, or treatment of status epilepticus
CA3112166A1 (en) * 2018-09-21 2020-03-26 Sk Biopharmaceuticals Co., Ltd. Carbamate compound and use of formulation comprising same in preventing, alleviating, or treating acute stress disorder or post-traumatic stress disorder
CA3157788A1 (en) * 2019-11-22 2021-05-27 Ji Hye Lee Oral pharmaceutical composition comprising carbamate compound and preparation method therefor

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3415840A (en) 1965-10-22 1968-12-10 American Home Prod Pyrazole-1-ethanol derivatives
DE2628420A1 (de) * 1976-06-24 1978-01-05 Bayer Ag 1-acyloxy-2-imidazolyl-1-phenyl- aethane, verfahren zu ihrer herstellung sowie ihre verwendung als fungizide und nematizide
US4349556A (en) * 1976-06-24 1982-09-14 Bayer Aktiengesellschaft Pesticidally active 1-acyloxy-1-phenyl-2-azolyl-ethanes
EP1461309A1 (en) * 2001-12-21 2004-09-29 Ortho-McNeil Pharmaceutical, Inc. Process for preparing 2-(substituted phenyl) - 2 - hydroxy-ethyl carbamates
US20060194873A1 (en) * 2004-09-16 2006-08-31 Choi Yong M Methods of treating epileptogenesis and epilepsy
US7598279B2 (en) * 2005-04-22 2009-10-06 Sk Holdings Co., Ltd. Neurotherapeutic azole compounds
AU2009348523B2 (en) 2009-06-22 2015-02-26 Sk Biopharmaceuticals Co., Ltd. Method for preparation of carbamic acid (R)-1-aryl-2-tetrazolyl-ethyl ester
US8404461B2 (en) 2009-10-15 2013-03-26 SK Biopharmaceutical Co. Ltd. Method for preparation of carbamic acid (R)-1-aryl-2-tetrazolyl-ethyl ester
US9108368B2 (en) 2009-10-16 2015-08-18 Novartis Ag Apparatus and method for transporting contact lenses through dipping baths

Similar Documents

Publication Publication Date Title
JP2015024998A5 (enExample)
JP2009504763A5 (enExample)
JP2016506916A5 (enExample)
JP2016512531A5 (enExample)
JP2015532295A5 (enExample)
JP2014511892A5 (enExample)
JP2015528471A5 (enExample)
JP2016518437A5 (enExample)
JP2019501133A5 (enExample)
JP2019500387A5 (enExample)
JP2017530984A5 (enExample)
JP2017531619A5 (enExample)
JP2016536286A5 (enExample)
JP2016534063A5 (enExample)
JP2017518334A5 (enExample)
JP2016517851A5 (enExample)
JP2014511891A5 (enExample)
JP2016534148A5 (enExample)
JP2020097577A5 (enExample)
JP2017141277A5 (enExample)
JP2016515561A5 (enExample)
JP2019521988A5 (enExample)
JP2013542261A5 (enExample)
JP2016040288A5 (enExample)
RU2017112048A (ru) Синергистические комбинации ауристана